Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

31 oct. 2023 08h15 HE | Source: Panbela Therapeutics, Inc.

Panbela Announces Validation of European Patent in UK, Italy, Germany, France, and Spain for Claims of a Novel Process for the Production of SBP-101

MINNEAPOLIS, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical-stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients...
25 oct. 2023 08h15 HE | Source: Panbela Therapeutics, Inc.

Acceptance of Polyamine Inhibitor CAR-T Combination Abstract for Online Publication

MINNEAPOLIS, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet...
24 oct. 2023 08h15 HE | Source: Panbela Therapeutics, Inc.

Panbela to Host Third Quarter 2023 Earnings Conference Call on November 9, 2023

MINNEAPOLIS, Oct. 24, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet...
26 sept. 2023 08h15 HE | Source: Panbela Therapeutics, Inc.

Panbela Announces Issuance of New Patent in China for Claims of a Novel Process for the Production of SBP-101

MINNEAPOLIS, Sept. 26, 2023 (GLOBE NEWSWIRE) -- (Nasdaq: PBLA), a clinical-stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with urgent unmet medical...
19 sept. 2023 08h15 HE | Source: Panbela Therapeutics, Inc.

Panbela to Present at the LD Micro Investor Conference

MINNEAPOLIS, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical-stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients...
05 sept. 2023 08h15 HE | Source: Panbela Therapeutics, Inc.

Panbela Announces Issuance of New Patent in Chile for Claims of a Novel Process for the Production of Flynpovi

MINNEAPOLIS, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical-stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients...
28 août 2023 08h15 HE | Source: Panbela Therapeutics, Inc.

Panbela to Present at H.C. Wainwright 25th Annual Global Investment Conference

MINNEAPOLIS, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical-stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients...
14 août 2023 08h15 HE | Source: Panbela Therapeutics, Inc.

Panbela Announces Issuance of New Patent in Europe for Claims of a Novel Process for the Production of SBP-101

MINNEAPOLIS, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical-stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients...
10 août 2023 16h10 HE | Source: Panbela Therapeutics, Inc.

Panbela Provides Business Update and Reports Q2 2023 Financial Results

MINNEAPOLIS , Aug. 10, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet...
31 juil. 2023 16h15 HE | Source: Panbela Therapeutics, Inc.

Panbela to Host Second Quarter 2023 Earnings Conference Call on August 10, 2023

MINNEAPOLIS, July 31, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet...

Page précédente

Page suivante